About US
Contact us
-
BTG launches DC Bead LUMI for liver cancer patients in CanadaBTG International has launched a next-generation treatment option, DC Bead LUMI, for cancer patients in Canada, marking its first worldwide market commercialisation. Based on the technology platfor2016/12/27
-
Deals this week: Incyte Corporation, Orexigen Therapeutics Ireland, Mitsubishi Tanabe Pharma CorporationUS-based biopharmaceutical companyIncyte Corporationhas entered a distribution agreement for the commercialisation of its drug named Iclusig (ponatinib) in Greece with GENESIS Pharma. The agreement w2016/12/26
-
M&As this week: CiToxLAB, Sichuan Kelun PharmaFrench-based pre-clinical services providerCiToxLAB Grouphas announced that it has acquired a pre-clinical contract research company known as AccelLAB. "The acquisition is expected to foster the acqu2016/12/26
-
European research groups partner to develop new vaccine against Zika virusResearch groups in Europe have joined forces to develop a new vaccine against the Zika virus. The ZIKAVAX consortium is supported by €5m funding from the EU's Horizon 2020 programme and comprises The2016/12/23
-
Sanofi’s Jevtana drug receives SMC approval to treat prostate cancerThe Scottish Medicines Consortium (SMC) has accepted Sanofi Genzyme’s Jevtana (cabazitaxel) for routine use in NHS Scotland to treat metastatic hormone-refractory prostate cancer (mHRPC). Jevtana (ca2016/12/23
-
Herantis Pharma secures EU Horizon 2020 programme grant for Parkinson studyFinnish company Herantis Pharma has secured a grant from the European Union (EU) for the Phase I-II clinical study with its drug candidate cerebral dopamine neurotrophic factor (CDNF) to treat Parkins2016/12/22
-
Strides Shasun to acquire Perrigo API IndiaIndian pharmaceutical company Strides Shasun has entered agreements to acquire complete shares in Perrigo API India for Rs1bn ($14.81m). Pursuant to the merger with Shasun Pharmaceutical in 2014, Str2016/12/22
-
EMA accepts Sanofi and Regeneron’s MAA for DupixentSanofi and Regeneron Pharmaceuticals’ marketing authorisation application (MAA) for Dupixent (dupilumab) has been accepted for review by the European Medicines Agency (EMA). Dupixent is being investi2016/12/21
-
AstraZeneca and Eli Lilly partner to co-develop Alzheimer’s disease treatmentUK-based AstraZeneca and Eli Lilly have signed an agreement to co-develop a new antibody selective for amyloid-beta 42 (Aβ42) for Alzheimer’s disease (AD) treatment, known as MEDI1814. At present, Aβ2016/12/21
-
UK’s CRT Pioneer Fund to invest in new blood cancer drugsUK’s Cancer Research Technology (CRT) Pioneer Fund has announced an investment to develop a new class of drugs for blood cancer, which will target a protein called B-cell lymphoma 6 (BCL6). Scientist2016/12/20